Jazz slashes expected IPO price, follows “date rape” controversy
Jazz Pharmaceuticals, the generally unexciting specialty-pharmaceutical maker that hoped to raise $179.4 million in an IPO, has collided with reality.
The Palo Alto, Calif. company today slashed its expected IPO price by a fifth.
We’ve written before about Jazz and its wildly overrated strategy of salvaging poorly… Continue Reading